4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $47.14 Consensus Target Price from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $47.00.

Several equities analysts have commented on the company. Cantor Fitzgerald downgraded 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. Leerink Partners reissued an “outperform” rating and set a $36.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Chardan Capital reissued a “buy” rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Finally, Royal Bank of Canada dropped their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in FDMT. Entropy Technologies LP purchased a new position in shares of 4D Molecular Therapeutics in the 1st quarter valued at approximately $239,000. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of 4D Molecular Therapeutics by 10.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 706,000 shares of the company’s stock worth $14,819,000 after buying an additional 65,000 shares during the period. Kennedy Capital Management LLC acquired a new position in shares of 4D Molecular Therapeutics in the 1st quarter valued at $4,358,000. Sofinnova Investments Inc. raised its stake in 4D Molecular Therapeutics by 36.8% in the 2nd quarter. Sofinnova Investments Inc. now owns 271,155 shares of the company’s stock worth $5,692,000 after acquiring an additional 72,969 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in 4D Molecular Therapeutics by 702.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after acquiring an additional 3,026 shares during the period. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Stock Performance

FDMT opened at $8.32 on Tuesday. The stock’s 50 day moving average price is $10.17 and its 200-day moving average price is $16.90. 4D Molecular Therapeutics has a one year low of $7.32 and a one year high of $36.25. The stock has a market cap of $384.63 million, a price-to-earnings ratio of -2.92 and a beta of 2.82.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.